Cardiovascular death represents the single largest cause of mortality in women with 70% of deaths attributable to modifiable risk factors, such as hypertension. This analysis aims at evaluating, whether there are gender disparities in antihypertensive drug usage and blood pressure (BP) control. We included 18 017 patients with arterial hypertension from the International Survey Evaluating Microalbuminuria Routinely by Cardiologists in patients with Hypertension (I-SEARCH). The study was conducted between September 2005 and March 2006 in 26 countries, and data on patient demographics, cardiovascular disease and risk factors, BP, and cardiovascular drug treatment were collected. Mean systolic blood pressure (SBP) was 2.1 mm Hg higher in women (150.6 ± 0.35 mm Hg, n ¼ 8357/18 017) than in men (148.5 ± 0.35 mm Hg; Po0.0001, n ¼ 9526/18 017), whereas no difference in diastolic BP was seen (88.2 ± 0.20 vs 88±0.20 mm Hg; P ¼ 0.198). Gender differences in SBP were more pronounced in diabetic as compared with nondiabetic patients (3.5 vs 1.7 mm Hg, n ¼ 4272 vs n ¼ 13 611; Po0.0001) and became evident at an age 55 years old. Overall BP-control rate was 33.6% in men and 30.6% in women (Po0.0001) and was lower in diabetic as compared with non-diabetic patients. In all, 30% of patients used one, 40% used two and 30% used X3 drugs without gender differences. Response rates to different drug regimens appeared to be similar. However, women received more frequently thiazides and b-blockers, and less frequently ACE-inhibitors as monotherapy. Major efforts are required to improve BP-management, especially in women.
Introduction
Arterial hypertension represents a major therapeutic challenge to health-care systems, affects almost one billion people worldwide and its prevalence is expected to increase from 26.4% in 2000 to 29.2% in 2025. 1 Although various pharmacological treatment options exist, BP control is suboptimal and major efforts are necessary to improve patients' awareness and compliance as well as physicians' adherence to treatment guidelines. 2, 3 Whereas recent evidence suggests that the association of blood pressure (BP) and the risk of ischaemic heart disease and stroke is similar in men and women and that BP lowering provides broadly similar mortality benefits, irrespective of the drug regimen used, other data suggest potential gender differences with regard to treatment efficacy. [4] [5] [6] [7] Furthermore, women with known cardiovascular disease or cardiovascular risk factors are less likely to receive guideline-recommended drug therapy as compared with men, and BP-control rates appear to be lower in women at a higher age. [8] [9] [10] [11] As cardiovascular disease is considered to be the single largest cause of mortality in women with 70% of cardiovascular deaths attributable to modifiable risk factors, such as hypertension, it is important to better understand gender disparities in hypertension management on a worldwide basis to ensure equal standards in treatment for both, men and women. 12 This analysis from a large international survey in hypertensive patients aims at analysing, whether there are gender disparities with regard to BP levels, BP control and antihypertensive drugs usage.
Patients and methods
A large international survey was conducted in 26 countries in Europe, North America, Latin America, Middle East and Asia as well as in Turkey, Australia and Morocco between 14 September 2005 and 24 March 2006. In total, 22 282 consecutive patients, aged 418 years with currently treated or newly diagnosed arterial hypertension (seated systolic/ diastolic blood pressure (SBP/DBP) 4140/90 mm Hg at the office visit) were screened, out of which 21 794 patients gave written informed consent. Patients were enroled by hospital-based cardiologists or in the outpatient cardiology setting. Furthermore, data on patient demographics, cardiovascular risk profile-and co-morbidities, BP, antihypertensive-and cardiovascular drug therapy were collected on a case report form as described elsewhere. 13 Table 2 . Similar results were obtained after additionally adjusting for waist circumference (data not shown).
SBP and DBP in men and women by age group Systolic blood pressure was 148.3 ± 2. 79 mm Hg at the age of 35-39 years in men and was not significantly higher at higher age (149.1±1.15 mm Hg at the age of X75 years). In contrast, in women, BP was 148.2 ± 2.92 mm Hg at the age of 35-39 years and 153.7±1.14 mm Hg at the age of X75 years. A significant gender difference in SBP was observed at the age of X55 years, in which SBP in women was about 2 mm Hg higher as compared with men (Po0.05 for all age groups X55 years). DBP was lower at higher age (93.3 ± 1.88 mm Hg in men and 93.1 ± 1.97 mm Hg in women at the age of 35-39 years and 82.9±0.68 mm Hg in men and 83.8±0.67 mm Hg in women at the age of X75 years, P ¼ 0.031). At the age of 45-49 and 50-54 years DBP was significantly higher in men as compared with women (P ¼ 0.021 and P ¼ 0.017, respectively). For details, see Figure 1 .
Pulse pressure in men and women by age group The pulse pressure was 55±2.00 mm Hg in men and 55.1 ± 2.10 mm Hg in women at the age of 35-39 years (P ¼ 0.9854), compared with 66.3±0.97 mm Hg in men and 69.9±0.96 mm Hg in women (Po0.0001) at the age of X75 years. The gender difference became statistically significant at an age higher than 45-49 years. For details, see Figure 2 .
Blood pressure-control rates in men and women with or without diabetes mellitus Systolic blood pressure-control rates. In the overall population, SBP control was achieved in 37.7%. (36.69-38.75%) of men and 34% (32.92-35.06%) of women (Po0.0001). In patients without diabetes, 42.3% (41.12-43.51%) of men and 39.2% (37.91-40.42%) of women achieved SBP control (P ¼ 0.0004), whereas SBP control was achieved in only 22.8% (21.08-24.65%) of diabetic men and 18.8% (17.03-20.64%) of diabetic women (P ¼ 0.0018). For details, see Figure 3 .
Diastolic blood pressure-control rates. Diastolic blood pressure control was 63.6% (62.61-64. 66%) in the overall population in men as compared with 64.1% (63.01-65.19%) in women (P ¼ 0.545). In patients without diabetes, DBP was controlled Figure 3 .
Overall blood pressure-control rates. Figure 6 .
Discussion
This analysis provides insights from a recent, large international study in men and woman with currently treated or newly diagnosed arterial hypertension. Earlier data from NHANES (1999) (2000) (2001) (2002) (2003) (2004) has shown significant gender disparities in BP levels, in which SBP was about 4 mm Hg higher in women, but DBP was 3.5 mm Hg lower than in men, resulting in a trend towards a lower BP-control rate in women (50.8% men vs 55.9% women uncontrolled).
14 These findings are supported by data from the Framingham cohort, in which control rates in women 460 years old were markedly lower than in men. 11 However, another analysis from a large sample of patients, including five European countries, suggested higher BP-control rates in women as compared with men, which differed from country to country. 15 Our data from an international sample of pharmacologically treated patients shows a significantly higher mean SBP ( 2.1 mm Hg), but no difference in mean DBP ( 0.2 mm Hg) in women as compared with men, resulting in a SBP-control rate of 37.7% in men, but only 34% in women. The overall BPcontrol rate was generally low, and significantly lower in women (30.6%) as compared with men (33.6%), driven by the observed disparity in SBP. When looking at patients with concomitant diabetes mellitus, overall BP-control rate was not only expectedly lower, but gender disparity in SBP levels was more pronounced (3.5 mm Hg); data that have been described earlier by Kjeldsen et al. 12 in a large survey conducted in Europe. Although the absolute difference in BP-control rate seems somewhat small, the detected difference in mean SBP of 2.1 mm Hg (3.5 mm Hg in the diabetic population) appears to be clinically meaningful, because it has been shown that a decrease in mean SBP of 2 mm Hg is associated with a 7% reduction in ischaemic heart disease-mortality and a 10% reduction in stroke-mortality. 16 Furthermore, the potential health burden of the observed gender disparity in SBP levels at an age X55 years is even more concerning in light of the fact that the prevalence of hypertension appears to be higher in elderly women than men. 17 Our data also shows significant gender disparities with regard to pulse pressure, occurring already at the age of 45 years, about 10 years earlier than the observed differences in SBP. This finding highlights the importance of using pulse pressure at an early stage of hypertension as a risk stratification tool, because pulse pressure-as opposed to SBP and DBP alone-has been shown to be a better predictor for adverse outcomes, especially in women. 18 Data from previous large hypertension trials have shown that most patients need combination therapy Figure 6 Blood pressure (BP) control rates for guideline-recommended dual therapies (percentage with 95% CI, adjusted for age, diabetes and ethnicity; for abbreviations see Figure 5a ; # Po0.05 for gender differences). to achieve sufficient BP control. However, in only 50% of trials, patients actually reached this goal. 19 Recent data from NHANES (1999) (2000) (2001) (2002) (2003) (2004) shows that approximately 30% of patients were treated with two drugs and 15% of patients with three or more antihypertensive drugs, and no gender differences could be detected; 20 findings that were also confirmed by a recent cross-sectional US-survey in about 12 000 patients treated in the primary care setting. 21 Our data do not show gender disparities in the usage of antihypertensive drug combination therapy and indicates, that physicians obviously apply international treatment guidelines equally well to men and women, irrespective of the presence or absence of controlled BP. Nevertheless, gender disparities with regard to SBP levels and BP control are more pronounced in diabetics. Our data further shows that more antihypertensive drugs are prescribed to both, diabetic men and women.
Another potential explanation for the observed gender disparities in BP control could be a preferential prescription of certain antihypertensive drug classes in men or women. Our analysis shows no major differences in the prescription of certain drug classes. However, significantly less ACE-Is as monotherapy, but more thiazides (monotherapy and combination therapy) and b-blockers (monotherapy) were prescribed in women, data that have been described by other groups. 11, [20] [21] [22] These findings might be partly explained by the threefold increased risk of women to develop ACE-inhibitor-related cough or potential beneficial effects of thiazides on bone density in postmenopausal women. 23, 24 Furthermore, safety concerns in prescribing ACEs to women of childbearing age might have contributed to the lower number of ACE-inhibitor prescriptions. However, only a small proportion of women aging 18-40 years were included (2.5%), and about two-thirds of women were 460 years old. According to our data, a high proportion of patients (440%) used non-guideline-recommended dual-combination therapy, the majority b-blockers together with RAS-blocking agents. It can only be speculated, why b-blockers and ACE-Is were the most frequently prescribed combination therapy overall, and why there was a significantly higher prescription rate of this combination in men as compared with women, whereas no such gender difference could be observed for b-blockers and ARBs. However, 28% of men but only 15.2% of women had coronary artery disease, in which b-blockers and ACE-Is are a recommended and inexpensive standard therapy. Furthermore, men had more frequently congestive heart failure, left ventricular hypertrophy and a history of atrial fibrillation, all of which can be effectively treated with b-blockers and ACE-Is.
Our study did not analyse, whether antihypertensive drugs were dosed differently in men and women. However, it has been shown, that women seem to be more prone to develop side effects and might metabolise antihypertensive agents differently, factors that could also have an effect on drug dosing. 25 Thus, drug doses might have been lower in women. Furthermore, gender differences in drug response (ability to control BP) might contribute to the lower BP-control rates observed in women. Our data indicate broadly similar BP-control levels in all guideline-recommended dual therapies and supports findings from a recent large analysis in more than 100 000 patients from prospective clinical trials, in which BP reduction appeared to be comparable in men and women, irrespective of drug classes used. 6, 26 However, our data have to be interpreted with caution because of the observational design of our study, which did not take into consideration gender differences in patient profiles and BP levels before initiation of antihypertensive treatment in the different patient groups.
In summary, our data from a recent worldwide study in pharmacologically treated hypertensive patients reveal a poorer BP control and a higher pulse pressure in women as compared with men. These differences were because of higher SBP levels in women at the age of X55 years. Gender disparities with regard to SBP levels appeared to be more pronounced in diabetics, and differences in pulse pressure were detected about 10 years earlier than disparities in SBP. Combination therapy was prescribed equally to both men and women and drug response to guideline-recommended dual therapy appeared to be similar, but gender disparities with regard to antihypertensive drug class prescription, drug dosage or drug response could represent potential explanations for our findings. Generally, BP-control rates were low, because only one-third of patients achieved the BP goal. Major efforts are required to improve BP control in both, men and women.
What is known about topic K The association of blood pressure (BP) and the risk of ischaemic heart disease and stroke is similar in men and women. K BP lowering appears to provide similar mortality benefits in men and women, irrespective of the drug regimen used. K Women with cardiovascular disease are less likely to receive guideline-recommended drug therapy as compared to men.
What this study adds K BP-control rate is significantly lower in women as compared to men. Gender disparities in systolic blood pressure (SBP) are more pronounced in diabetic patients. K Women have a higher pulse pressure than men, differences which become apparent at an age of 45 years. K There are no gender disparities in the number of drugs prescribed, but women are more frequently treated with thiazides and b-blockers and less frequently with ACE-inhibitors as monotherapy.
